NCT03918148View on ClinicalTrials.gov

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

CompletedOBSERVATIONAL
Enrollment

1,150

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SGLT-2i

Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin

DRUG

DPP-4i

Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin

Trial Locations (1)

80138

Unit of Diabetes, Naples

All Listed Sponsors
lead

University of Campania Luigi Vanvitelli

OTHER

NCT03918148 - Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA) | Biotech Hunter | Biotech Hunter